Last Updated : April 21, 2023
Details
Generic Name:
tralokinumab
Project Status:
Pending
Therapeutic Area:
atopic dermatitis (AD)
Manufacturer:
LEO Pharma Inc.
Call for patient/clinician input open:
Brand Name:
Adtralza
Project Line:
Reimbursement Review
Project Number:
SR0787-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and who had an adequate trial or be ineligible for each of the following therapies: phototherapy (where available) and off-label immunosuppressants.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Adtralza (tralokinumab injection) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adtralza can be used with or without topical corticosteroids.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : April 21, 2023